LEXINGTON, Mass. March 28, 2024 - T2 Biosystems, a renowned leader in rapid sepsis pathogen detection and antibiotic resistance gene identification, has announced the extension of its multi-year capital equipment supplier agreement with Vizient, Inc. This agreement, which now runs through March 31, 2025, strengthens T2 Biosystems’ position as a key provider of advanced medical diagnostics solutions in the United States.
Under this agreement, T2 Biosystems will continue to supply Vizient with three vital products: the T2Dx Instrument, the T2Bacteria Panel, and the T2Candida Panel. These cutting-edge diagnostic tools enable the direct detection of both bacterial and fungal pathogens responsible for sepsis, directly from a patient’s whole blood sample.
Vizient, Inc. is the largest member-driven healthcare performance improvement company in the United States. This partnership enables T2 Biosystems to extend its reach and impact by providing their state-of-the-art technology to healthcare facilities across the country. The decision to extend the agreement demonstrates the continued trust and confidence that Vizient has in T2 Biosystems’ innovative diagnostic solutions.
Sepsis is a life-threatening condition that occurs when the body’s response to an infection causes damage to its own tissues and organs. Rapid and accurate identification of the pathogens causing sepsis is crucial for effective treatment. T2 Biosystems’ products offer a revolutionary approach as they significantly reduce the time required for diagnosing sepsis-causing pathogens, compared to traditional methods which can take up to several days.
The T2Dx Instrument, combined with the T2Bacteria and T2Candida Panels, streamlines the diagnosis process by enabling healthcare professionals to detect the presence of bacterial and fungal pathogens directly from a patient’s blood sample, without the need for blood culture. This allows for faster and more targeted treatment decisions, reducing the risk of severe complications and improving patient outcomes.
T2 Biosystems’ dedication to developing advanced medical diagnostics solutions has garnered recognition and trust from healthcare professionals and institutions across the United States. The continued partnership with Vizient, Inc. emphasizes the importance of T2 Biosystems’ technology in addressing the critical need for rapid, accurate diagnostics in sepsis management.
With the extension of the capital equipment supplier agreement, T2 Biosystems is well-positioned to continue innovating in the field of sepsis diagnosis, contributing to advancements in patient care and overall healthcare system efficiency.
Comments